BMS-986020 Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 370

Clinical Trials

BMS-986020, a lysophosphatidic acid receptor antagonist, has been evaluated in several completed clinical trials sponsored exclusively by Bristol-Myers Squibb. Encompassing Phase 1 and Phase 2 protocols, these studies investigated therapeutic applications in idiopathic pulmonary fibrosis, immunology, and immunosuppression. Phase 1 trials evaluated human pharmacokinetics, metabolism, safety, and concomitant drug interactions, while a Phase 2 trial assessed safety and therapeutic efficacy in patients with idiopathic pulmonary fibrosis.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02101125	Completed	Immunosuppression For Disease	Bristol-Myers Squibb	2014-03	Phase 1
NCT02068053	Completed	Immunosuppression For Disease	Bristol-Myers Squibb	2014-03	Phase 1
NCT02017730	Completed	Immunology	Bristol-Myers Squibb	2014-01	Phase 1
NCT01766817	Completed	Idiopathic Pulmonary Fibrosis	Bristol-Myers Squibb	2013-01-31	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the BMS-986020 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

BMS-986020 functions as a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1), blocking LPA-mediated pro-fibrotic signal transduction pathways and downregulating downstream intracellular activation. By suppressing LPA1-driven fibroblast proliferation, cell migration, and extracellular matrix deposition, BMS-986020 attenuates pathological tissue remodeling, demonstrating therapeutic relevance for the treatment of idiopathic pulmonary fibrosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).